Smithkline Beecham Corporation

Glaxosmithkline LLC

Other

Human Genome Sciences, Inc.

Beth Israel Deaconess Medical Center, Inc.

Glaxosmithkline Intellectual Property Development Limited

Zdenka Ludmila Jonak

Kyung Oh Johanson

Stephen H Trulli

Alexander H Taylor

John Richard White

Alan Peter Lewis

Jonathan Henry Ellis

Christine Marie Debouck

Volker Germaschewski

Narendra B Bam

Robert B Kirkpatrick

Cheryl Ann Janson

Stephanie Jane Clegg

Eric Dobrzynski

John Robert White

Gregg A Hastings

Xiayang Qiu

Robert Clark

Jacob Bongers

Xianyang Qiu

Ping Yeh

James A Fornwald

Alexander Harrison Taylor

Yu Xue

Jonathan Alexander Terrett

Judithann M Lee

Zdenka Haskova

Alexis Paul Godillot

Neil James Clarke

Alexis Pual Godillot

Christopher B Hopson

Kyung O Johanson

Jacab S Bongers

Ping-Yang Yeh

The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.

Antigen binding proteins

The present invention relates to an antibody which has multiple specificities. In particular the antibody of the present invention binds to (cross react with) human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78.

Compounds

Methods of treating cancer in patients in need thereof with human interleukin-18 (IL-18) polypeptides and substitution mutants thereof that are conjugated to water-soluble polymers at specific sites on the human IL-18 protein are disclosed.

Method of treating cancer by administering conjugates comprising human IL-18 and substitution mutants thereof

This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin &#x3b1;&#x3b2;receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of &#x3b1;&#x3b2;-mediated disorders, such as restenosis, in human patients.

[object Object]

Human interleukin-18 (IL-18) polypeptides and substitution mutants thereof were conjugated to water-soluble polymers at specific sites on the human IL-18 protein. These conjugated human IL-18 and substitution mutants thereof retain biological activity. These conjugated cytokines demonstrate enhanced and unexpected biological properties when compared to the corresponding unconjugated cytokines.

Conjugates comprising human IL-18 and substitution mutants thereof

Anti-alphabeta3 humanized monoclonal antibodies

The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.

METH1 polynucleotides

This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human &#x3b1;subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.

Nucleic acids encoding anti-human &#x3b1;&#x3bd;&#x3b2;3 and &#x3b1;&#x3bd;&#x3b2;5 antibodies

This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human .alpha..sub.v subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.

Anti-human .alpha..sub.v .beta..sub.3 and .alpha..sub.v .beta..sub.5

The present invention provides mammalian cells modified to stably express at least the entire human immunodeficiency virus-1 envelope protein gp160. The invention provides a vaccine comprising the cells of the invention. The invention also provides methods for screening compounds for their ability to inhibit formation of syncytia between cells that express HIV-1 gp160 and cells that express CD4 comprising mixing cells of invention, cells that express CD4 on their surfaces, and a test compound for a length of time sufficient for syncytia to form; and then determining the amount of syncytia formation.

Human lymphoid cells expressing human immunodeficiency virus envelope

Growing community of inventors

King of Prussia, PA, United States of America

Zdenka Ludmila Jonak